StockNews.AISignal intelligencePublic signal · 1-minute delayed
Source-backed market context you can read and share without an account.
The decline of 15% highlights investor concern over the dilution from the new offering. Historical patterns show that large offerings often precede temporary stock price declines.
What happened, with direct paths to the underlying reporting
ACET shares fell 15% after $80 million direct offering announcement. Early ADI-001 trial data shows 100% renal response in lupus nephritis patients. Company plans to request FDA meeting for Phase 2 trial design in 2026. Stock reached $1.30 in premarket before news caused sharp decline.
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.